Sólo acción del precio: los movimientos de Guardant Health Inc. (GH) marcan la pauta para los modelos institucionales. Cómo afecta Guardant Health Inc. (GH) el momento de la estrategia de rotación

A Cancer Test Approval Meets a High Valuation Guardant Health, Inc. (NASDAQ:GH) is moving beyond identifying mutations at diagnosis toward testing patients repeatedly as their cancer changes. Recent FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant in advanced breast cancer reinforces that shift. The financial opportunity is not merely another test […]

PALO ALTO, Calif., October 20, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Three prior sales of 116 shares each generated $18,148 to $20,300 apiece. The proposed sale date is approximately October 16, 2026.